Discover 183 paid clinical trials in North Dakota. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
North Dakota offers many paid research opportunities statewide, giving healthy volunteers and individuals with specific health needs access to a wide range of clinical studies. Key cities like Fargo, Bismarck, and Grand Forks are home to research centers actively recruiting participants, offering access to the latest treatments and medical advancements.
Filter
1
Filter results
Results: 183
Active & Responsive
VK2735 for Weight Management Phase 3
for
Weight Loss
Location: Fargo ND, Omaha NE, West Des Moines IA, Denver CO,
Sponsor: Viking Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07104500
Phase3, Recruiting
New
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
for
Rectal Cancer
Location: Bismarck ND, Fargo ND, Winnipeg, Bemidji MN,
Sponsor: Canadian Cancer Trials Group
Sex: All
Age: 18+
Code: NCT06205485
Phase3, Recruiting
Alcohol Related Impairment and Reinforcement: Pre to Post Roux en Y Gastric Bypass Surgery
for
Bariatric Surgery Candidate
Location: Fargo ND
Sponsor: Neuropsychiatric Research Institute, Fargo, North Dakota
Sex: All
Age: 21 - 65
Code: NCT02370732
Recruiting
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
for
Cancer
Location: Fargo ND, Hannibal MO, Rolling Meadows IL, Peoria IL,
Sponsor: Tempus AI
Sex: All
Age: 18 - 70+
Code: NCT06207032
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)